secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPID MICRO BIOSYSTEMS, INC. (RPID)
CIK:        0001380106
Form:       8-K
Filed at:   2023-03-03T23:59:59+00:00
Accession:  0001380106-23-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapid Micro Biosystems Q4 commercial revenue $4.4M, FY2022 $17.1M; guides FY2023 at least $22M
--------------------------------------------------------------------------------

- Q4 2022 commercial revenue $4.4M (vs $4.9M prior year); net loss $16.4M ($0.39 per share).
- Full year 2022 commercial revenue $17.1M (vs $21.6M prior year); net loss $60.8M ($1.43 per share).
- Recurring commercial revenue grew 28% in Q4 to $2.9M; full year recurring revenue $11.0M (+40% YoY).
- Placed 2 new systems in Q4, 9 in full year; cumulative 125 placed, 103 validated systems.
- FY2023 guidance: commercial revenue at least $22M, with at least 15 new system placements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/0001380106-23-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1380106/000138010623000011/rpid-20230303.htm
  HTML page:      https://secwatch.observer/filing/0001380106-23-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer